Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
暂无分享,去创建一个
M. Rezai | P. Fasching | A. Schneeweiss | H. Tesch | S. Loibl | M. Untch | V. Nekljudova | J. Blohmer | G. von Minckwitz | J. Huober | C. Jackisch | C. Schem | C. Hanusch | V. Müller | C. Solbach | C. Salat | P. Klare | I. Witzel | D. Zahm | B. Ingold-Heppner | M. Reinisch | E. Laakmann | Jens-Uwe Blohmer | B. Ingold‐Heppner
[1] M. Rezai,et al. Abstract P1-17-01: Development of brain metastases in breast cancer patients treated in the neoadjuvant trials Geparquinto and Geparsixto , 2018 .
[2] K. Hunt,et al. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance) , 2017, Annals of surgery.
[3] P. Wen,et al. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study , 2017, JAMA oncology.
[4] W. Weichert,et al. 10PComparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls , 2017 .
[5] A. Schneeweiss,et al. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Z. Ren,et al. Breast cancer subtypes predispose the site of distant metastases. , 2015, American journal of clinical pathology.
[7] M. Rezai,et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] H. Iwata,et al. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis , 2014, Breast Cancer Research and Treatment.
[9] M. Rezai,et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[10] A. Giobbie-Hurder,et al. Challenges of guarantee-time bias. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Rezai,et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). , 2013, European journal of cancer.
[12] L. Tanoue,et al. The National Comprehensive Cancer Network , 1998, Cancer.
[13] S. Bhatia,et al. The shifting landscape of metastatic breast cancer to the CNS , 2013, Neurosurgical Review.
[14] E. Winer,et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network , 2012, Cancer.
[15] G. Hortobagyi,et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer , 2012, Cancer.
[16] J. Niland,et al. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study , 2012, Breast Cancer Research.
[17] A. Niemierko,et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype , 2012, Breast Cancer Research and Treatment.
[18] M. Rezai,et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. , 2012, The Lancet. Oncology.
[19] V. Kataja,et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study , 2011, Breast Cancer Research.
[20] G. Hortobagyi,et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] K. Pogoda,et al. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] V. Preedy,et al. Prospective Cohort Study , 2010 .
[24] M. Hayran,et al. Percent Positive Axillary Involvement Predicts for the Development of Brain Metastasis in High‐Risk Patients with Nonmetastatic Breast Cancer Receiving Post‐Mastectomy Radiotherapy , 2008, The breast journal.
[25] John W M Martens,et al. Subtypes of breast cancer show preferential site of relapse. , 2008, Cancer research.
[26] G. Hortobagyi,et al. Central nervous system metastases in patients with high‐risk breast carcinoma after multimodality treatment , 2004, Cancer.
[27] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .